Determinants of chemotherapy abandonment in Ethiopia: a nested case–control study
Nearly one-fifth of patients who started chemotherapy eventually abandoned their treatment. This means that patients experienced physical and financial toxicity as well as the efforts of health workers, but no treatment benefit. To avoid this, physicians need to closely follow the patients and explain the need to complete all chemotherapy cycles and treat side effects to avoid treatment abandonment with impaired survival. Additionally, attention must be paid to improving patient follow-up care during pandemics like COVID-19 and subsidizing therapy to ensure accessibility. Moreover, attention should be given to improving the subsidization of therapy and ensuring accessibility.
Authors
- Sefonias Getachew (ORCID: https://orcid.org/0000-0001-9506-1196)
- Nigussie Assefa Kassaw (ORCID: https://orcid.org/0000-0001-5420-0671)
- Adamu Addissie (ORCID: https://orcid.org/0000-0003-4709-3606)
- Muluken Gizaw
- Eva Johanna Kantelhardt (ORCID: https://orcid.org/0000-0001-7935-719X)
- Edom Seife
- Tigist Birie
- Yared Tilahun
Institutions
- University of South Australia (AU)
- Luther University (KR)
- Clinton Health Access Initiative (US)
- SA Health (AU)
- Asossa University (ET)
- Tikur Anbessa Hospital (ET)
- Addis Ababa University (ET)
- Martin Luther University Halle-Wittenberg (DE)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-03-30
- DOI
- https://doi.org/10.1093/oncolo/oyaf076
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- European Commission
- Deutscher Akademischer Austauschdienst
- Else Kröner-Fresenius-Stiftung
- Addis Ababa University